PLA2G7 and metabolic syndrome: After adjustment for dyslipidemia, coronary heart disease, hyperhomocysteinemia, and TOAST subtypes at baseline, the differences in Lp-PLA2 levels remained statistically significant among the four groups (80.1 ± 15.7 vs. 104.2 ± 15.0 vs. 109.0 ± 9.1 vs. 95.2 ± 10.4 μg/L, p = 0.044).